Laurion Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Laurion Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-332,189	Closed	-$76.9K	–	402
2024 Q3	$76.9K	Sell	332,189 -75,110	-18%	-$27.5K	﹤0.01%	257
2024 Q2	$221K	Sell	407,299 -13,127	-3%	-$10.4K	﹤0.01%	470
2024 Q1	$429K	Sell	420,426 -142,569	-25%	-$104K	﹤0.01%	436
2023 Q4	$321K	Sell	562,995 -135,005	-19%	-$82.9K	﹤0.01%	415
2023 Q3	$726K	Hold	698,000	–	–	﹤0.01%	378
2023 Q2	$984K	Hold	698,000	–	–	0.01%	368
2023 Q1	$1.11M	Hold	698,000	–	–	0.01%	299
2022 Q4	$1.02M	Hold	698,000	–	–	﹤0.01%	333
2022 Q3	$2.98M	Hold	698,000	–	–	0.02%	296
2022 Q2	$2.71M	Buy	+698,000	New	+$1.99M	0.04%	208

Other funds holding VIRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's VIRX Position: Q4 2024 in Review

Laurion Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 332,189 shares — an estimated $76.9K sold.

Laurion Capital Management first reported a position in VIRX in Q2 2022 and held it in 10 quarters. The position peaked at $2.98M in Q3 2022. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

Laurion Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Laurion Capital Management sold 332,189 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $76.9K.
Laurion Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2022 and held it in 10 quarters.
Laurion Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $2.98M in Q3 2022.
32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Laurion Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.